Penile Stretching Before and After: Why Girth Never Changes
Introduction: What “Before and After” Really Means for Penile Stretching
Men who search for “penile stretching before and after” are usually doing due diligence. Before committing months of daily effort and several hundred dollars to a traction device, they want proof that the investment will produce a change they can actually see.
The clinical literature offers a clear answer. Traction devices can modestly increase one measurement, stretched or flaccid length. The research is equally consistent that girth does not respond to traction.
Much of the before-and-after content circulating online conflates any measurable change with a visible, meaningful one. This article separates the clinical measurement researchers use from what a man sees in the mirror. It also flags a point that consumer content rarely mentions: most of the supporting data comes from men with Peyronie’s disease or post-prostatectomy shortening, not healthy men seeking cosmetic enlargement.
This is an evidence-based breakdown for men evaluating their options, not a sales pitch for stretching devices.
What Penile Stretching “Before and After” Photos Are Actually Measuring
Nearly every traction study relies on Stretched Penile Length (SPL). SPL is taken while the penis is pulled under manual tension. It does not reflect the relaxed flaccid state a man lives with daily, and it is not the same as erect length.
SPL is a reasonable research proxy because it is repeatable and standardized. The problem arises when marketing presents SPL gains as equivalent to real-world, visible gain.
Device-sales content often uses a “Month 3 / Month 6 / Month 12” progression styled as a dramatic transformation. These timelines rarely disclose that the numbers reflect length under tension rather than everyday appearance, and they rarely cite a single peer-reviewed source.
Where the Clinical Evidence Actually Comes From
The most rigorous randomized trials and reviews of penile traction therapy (PTT) were conducted in two groups:
- Men with Peyronie’s disease, where fibrous plaque causes curvature and shortening
- Men after radical prostatectomy, who often experience surgically induced length loss
In both groups, the goal is corrective: reversing fibrotic shortening or recovering lost length. That differs fundamentally from a healthy man’s goal of cosmetic size increase. Tissue that has contracted because of disease or surgery may respond to traction differently than anatomically normal tissue, so results from these populations may not generalize to healthy men the way marketing implies.
The Real Numbers: How Much Length Can Traction Actually Produce
With that caveat in place, the data does show real, if limited, length gains.
- Pooled review of 15 major studies (1,000+ patients): A contemporary narrative review of traction therapy for Peyronie’s disease found that modern devices such as RestoreX and Penimaster PRO produced average length gains of 1.5 to 2.3 cm, with adherence above 85% in trial conditions.
- The pivotal RestoreX randomized trial: Published in the Journal of Urology, this study found that 94% of Peyronie’s patients achieved some increase in length. Only 10.9% reached the top bracket of 1.6 cm. Most gain is modest; top-tier gain is rare.
- Pre-prosthesis lengthening study: A trial registered on ClinicalTrials.gov reported a 1.5 cm length increase at three months along with an 11.7-degree reduction in curvature compared with controls. These are corrective outcomes in men preparing for implant surgery, not cosmetic results.
- An older, frequently cited device study: Participants wore the device 6 hours per day for 4 months to achieve roughly 1.7 cm of gain.
Converted to inches, even the best-case results land at roughly 0.5 to 1 inch of stretched or flaccid length, a long way from the dramatic transformations implied by many online testimonials.
The Daily Time Investment Behind Every Gain
Consumer-facing clinical summaries consistently describe the same requirement: 4 to 6 hours of daily wear, sustained for 3 to 6 months.
Wear time drives results. In the RestoreX trial, gains were tightly linked to daily usage; men who wore the device less produced below-average results.
For a working professional, this becomes a practical cost-benefit question. Several hours of daily device wear must fit around meetings, travel, exercise, and family life, for months at a time. Few men can sustain that routine, and partial compliance largely erases the potential benefit.
Why Girth Doesn’t Move: The Mechanism Traction Can’t Touch
Traction works through mechanotransduction. Sustained axial tension along the shaft signals cells to proliferate and encourages fibrous tissue to elongate in the direction of the pull. The process is oriented toward length.
Traction stretches; it does not fill. It does not add tissue volume, and it does not increase circumference.
The research confirms this:
- A review in Translational Andrology and Urology reported that “the use of penile traction did not affect change in penile girth.”
- A study of a penile-extender device in men with shortened penises found no significant difference in proximal penile girth.
Across the available literature, no meaningful evidence shows that traction alone changes girth, and multiple independent reviews reach the same conclusion. For a man whose concern is thickness, no amount of wear time changes the underlying mechanism.
The Hidden Costs: Dropout Rates, Side Effects, and Regulatory Reality
Clinical trials report dropout rates of 30% to 50%, driven mainly by time burden and discomfort. Device marketing rarely mentions this figure.
Documented side effects of extended daily wear include:
- Skin irritation
- Bruising
- Temporary numbness
- Pressure marks
These dropout figures come from controlled trials, where participants receive structured protocols, monitoring, and follow-up. Even under those conditions, roughly a third to half could not sustain the regimen. Real-world adherence, without that support, is likely lower.
What the FDA and AUA Actually Say
Regulatory language matters here, and many sites get it wrong.
- FDA classification: External penile rigidity devices fall under 21 CFR 876.5020. That regulation explicitly excludes “mechanical penile extenders, penile enhancement/enlargement” from the intended use. As a result, no traction device is FDA-cleared for enlargement claims. Calling such a device “FDA-approved for enlargement” is inaccurate.
- Enforcement: The FDA has issued a warning letter to an extender manufacturer stating that devices intended for penile enhancement, such as penis enlargement, are outside the scope of that classification regulation.
- Urology Care Foundation (the AUA’s patient education arm): The foundation states that almost no method of penis augmentation works. It does not endorse traction devices pending more research on safety and effectiveness.
The terms are not interchangeable. FDA-approved refers to the premarket approval pathway. FDA-cleared refers to 510(k) clearance based on substantial equivalence. Not cleared for this use means the claim falls outside any authorization the product holds.
Length vs. Girth: Clarifying What You’re Actually Trying to Change
A 2025 meta-analysis of 36,883 clinician-measured men provides useful reference points:
| Measurement | Average |
|---|---|
| Flaccid length | ~9.2 cm (3.6 in) |
| Stretched length | ~12.9 cm (5.1 in) |
| Erect length | ~13.9 cm (5.5 in) |
| Erect circumference | ~11.7 to 11.9 cm (4.6 to 4.7 in) |
Against these baselines, a “successful” traction outcome of 1.5 to 2.3 cm represents a modest percentage change in stretched length. Circumference, the dimension most visually associated with size, stays statistically unchanged.
For men whose goal is a visibly thicker, fuller appearance rather than a documented SPL number, traction targets the wrong anatomical variable.
The Evidence-Based Alternative for Girth: HA Dermal Filler Augmentation
Hyaluronic acid (HA) dermal filler is a growing, evidence-backed category that targets girth directly, the dimension traction cannot influence. The data shows something the traction literature lacks: a predictable, dose-responsive pattern.
- Retrospective study of 155 men (Journal of Sexual Medicine): Average girth increase was 0.633 cm per treatment. Men receiving multiple treatments averaged 1.8 cm, and those with four or more treatments averaged nearly 3 cm.
- 18-month follow-up study: Girth increased from a baseline of 7.48 cm to 11.41 cm at one month and remained largely maintained at 11.26 cm through 18 months, with 94% patient satisfaction.
- Real-practice confirmatory study (World Journal of Men’s Health): HA filler girth enhancement produced significant, sustained improvements in girth, length, appearance satisfaction, and sexual satisfaction over one year without serious adverse events.
Regulatory disclosure: Neither the FDA nor the AUA has approved dermal fillers for penile use. Penile filler augmentation is an off-label application, and men should weigh the efficacy data with that in mind.
For contrast, the only FDA-cleared surgical device for cosmetic girth augmentation is the Penuma/Himplant silicone implant, cleared under 510(k) K220760 in 2022. It requires surgery. Filler is a non-surgical option in a landscape where regulatory clarity varies by modality.
Safety Profile: What the Filler Data Shows
Across cohorts ranging from 155 to 471 men, documented complications were generally low:
- Occasional injection-site infection
- Granulomas, which resolved with hyaluronidase
- Rare priapism, linked to concurrent intracavernosal injection use rather than the filler itself
Traction carries skin irritation, numbness, bruising, and a 30% to 50% dropout rate. Filler carries a different, low-frequency complication profile managed in a clinical setting. Neither option is risk-free, and each risk profile is tied to a different goal.
How Girth Augmentation Works in Practice: The Stoller Medical Group Approach
At Stoller Medical Group, girth enhancement uses Belefil®, an HA-based, medical-grade dermal filler placed beneath the penile skin. The procedure is performed in an outpatient setting in under one hour, with no cutting and no general anesthesia.
Staged treatment. The practice uses incremental sessions rather than one dramatic procedure. Staging supports symmetry and safety, and it is consistent with the dose-responsive data above, where additional treatments correlated with greater cumulative girth gain.
Recovery. Patients are typically back on their feet in about 10 days, and sexual activity can usually resume within 7 to 10 days. Other permanent filler types are associated with 40 or more days of recovery.
Reported outcomes. The practice reports:
- Girth increases of up to 1 to 1.5 inches
- 80% to 90% permanent improvement in girth and volume
- Results typically lasting 18 to 24 months
- Optional touch-up sessions, usually beginning with a follow-up 2 to 3 months after the initial treatment
Pricing. Treatment is priced by syringe. Cost starts at $7,500 and increases depending on the patient’s desired results. Most men begin with a minimum of 10 syringes, and the average first procedure uses 15 syringes. Pricing scales with the outcome a patient is pursuing rather than following a flat fee.
Combined treatments. Men seeking a more comprehensive result can add glans enlargement or scrotal enhancement during the same visit.
Traction vs. Filler: A Side-by-Side Look at the Evidence
| Factor | Penile Traction | HA Filler Augmentation |
|---|---|---|
| Primary dimension affected | Stretched/flaccid length | Girth (circumference) |
| Effect on girth | None demonstrated | 0.633 cm per treatment; ~1.8 to 3 cm with multiple treatments |
| Typical gain | 1.5 to 2.3 cm SPL (about 0.5 to 1 in) | Up to 1 to 1.5 in girth (practice-reported) |
| Time to result | 4 to 6 hrs/day for 3 to 6 months | Under one hour in-office; visible immediately |
| Adherence/dropout | 30% to 50% dropout in trials | Staged in-office sessions |
| Primary study populations | Peyronie’s disease, post-prostatectomy | Men seeking girth enhancement |
| Regulatory status | Not FDA-cleared for enlargement | Off-label; not FDA- or AUA-approved for penile use |
| Durability | Linked to ongoing wear compliance | Largely maintained through 18 months in follow-up data |
These are not competing solutions to the same problem. They address different anatomical variables, and a man’s actual goal should determine which evidence base applies to him.
Conclusion: Matching the Mechanism to the Goal
Penile traction has a real but modest evidence base for stretched or flaccid length gains. That evidence comes mainly from Peyronie’s disease and post-prostatectomy populations, under demanding daily wear protocols that many participants could not sustain.
Girth, by the literature’s own conclusions, does not respond to traction. For a man whose goal is visible thickness, traction is the wrong mechanism.
HA filler-based girth augmentation targets the dimension traction cannot influence. Its evidence base is growing and more consistent, though it remains an off-label use. The sound approach is to match the evidence-backed tool to the stated goal rather than defaulting to whichever product markets itself most aggressively.
Ready to Explore an Evidence-Based Path to Visible Girth Change?
Many accomplished men have assumed no realistic solution existed for this concern. A free, confidential consultation with Stoller Medical Group provides an individualized assessment of what girth-focused treatment can achieve for a specific anatomy and goal.
Dr. Roy B. Stoller is a board-certified physician with more than 25 years in aesthetic and restorative medicine, including five years focused specifically on non-surgical male enhancement. The practice has performed more than 15,000 enlargement procedures.
Consultations are available at five locations:
- Manhattan, 515 Madison Avenue
- Long Island, Jericho
- Albany, Latham
- Pennsylvania, Chadds Ford
- Minnesota, Eagan
Every consultation is discreet, professional, and medical-first. Pricing is clear from the outset: treatment is priced by syringe, starting at $7,500 and increasing with desired results. Most men begin with at least 10 syringes, averaging 15 during a first procedure.
Book a free consultation to receive a personalized assessment of girth-focused options grounded in the evidence above.
